Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets

Table 5

Tablet properties of the preliminary FDC of metformin HCl and glibenclamide ODTs.

Formulation code	Hardness (kg/cm^2)	Weight (mg)	Wetting time (seconds)	Drug content (%)
				MET	GLB
Fp1	5.30 ± 0.32	349.70 ± 1.88	57 ± 0.81	98.78 ± 1.33	100.83 ± 0.46
Fp2	8.05 ± 0.13	347.60 ± 2.59	80 ± 1.76	100.64 ± 1.08	102.29 ± 0.38
Fp3	4.11 ± 0.24	350.20 ± 2.25	28 ± 0.87	100.09 ± 1.11	104.10 ± 0.81
Fp4	7.81 ± 0.92	349.90 ± 2.28	49 ± 0.44	98.23 ± 0.88	101.84 + 0.22
Fp5	7.72 ± 0.06	349.6 ± 1.64	87 ± 2.05	97.51 ± 1.12	103.36 ± 0.43
Fp6	10.15 ± 0.41	349.50 ± 1.78	96 ± 0.42	100.26 ± 0.69	100.12 ± 0.61
Fp7	8.42 ± 0.28	352.90 ± 1.37	39 ± 0.49	97.80 ± 0.83	99.36 ± 0.26
Fp8	9.34 ± 0.22	349.00 ± 1.63	65 ± 0.79	98.27 ± 1.41	101.91 ± 0.36